Recombinant interferon alpha treatment decreases heart rate variability indices and impairs exercise tolerance in patients with chronic hepatitis

Biomedicine and Pharmacotherapy

Volumn 59, Issue SUPPL. 1, 2005, Pages

  Takase, B ^a   Hamabe, A ^a   Uehata, A ^b   Hujioka, T ^b   Kondo, T ^b   Matsui, T ^a   Ohsuzu, F ^a   Ishihara, M ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Japan Self Defense Forces Central Hospital   (Japan)

Author keywords

Ambulatory ECG monitoring; Arrhythmia; Cardiac function; Side effect of interferon therapy

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY MONITORING; EXERCISE TOLERANCE; FEMALE; FREQUENCY ANALYZER; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART PALPITATION; HEART RATE; HEART RATE VARIABILITY; HUMAN; ISCHEMIA; MALE; PRIORITY JOURNAL; RR INTERVAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC HYPERTENSION; TREADMILL EXERCISE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; AGED; ANTIVIRAL AGENTS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART RATE; HEPATITIS, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; RISK FACTORS;

EID: 27744500769     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(05)80025-3     Document Type: Article

References (26)

1. Lok AS, Heathcote EJ, and Hoofnagle JH Management of hepatitis B: 2000-summary of a workshop Gastroenterology 120 2001 1828 1853
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, and Goncales FL Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, and Garcia G A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype Am J Gastroenterol 95 2000 3225 3229
4. Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, and Peel KR Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study Br J Cancer 91 2004 621 626
5. Sonnenblick M, and Rosin A Cardiotoxicity of interferon; a review of 44 cases Chest 99 1991 5570 5661
6. Friess GG, Brown TD, and Wrenn RC Cardiovascular rhythm effects of gamma recombinant DNA interferon Investigational New Drugs 7 1989 275 280
7. Cohen MC, Huberman MS, and Nesto RW Recombinant alpha2 interferon-related cardiomyopathy Am J Cardiol 85 1988 549 551
8. Teragawa H, Hondo T, Amano H, Hino F, and Ohbayashi M Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C Jpn Heart J 37 1996 905 915
9. Teragawa H, Hondo T, Amano H, Watanabe H, Ohe H, and Hattori N Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C Jpn Heart J 37 1996 137 142
10. Tanaka H, Yamakado T, Emi Y, Nabeshima K, Itoh S, and Nakano T Interferon-induced coronary vasospasm: A case history Angiology 46 1995 1139 1143
11. Fauchier L, Babuty D, Cosnay P, and Fauchier JP Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy J Am Coll Cardiol 33 1999 1203 1207
12. Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, and Feldman CL Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study Circulation 94 1996 2850 2855
13. Algra A, Tijssen JG, Roelandt JR, Pool J, and Lubsen J Heart rate variability from 24-h electrocardiography and the 2-year risk for sudden death Circulation 88 1993 180 185
14. Aktas MK, Ozduran V, Pothier CE, Lang R, and Lauer MS Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program JAMA 292 2004 1462 1468
15. Balady GJ, Larson MG, Vasan RS, Leip EP, O'Donnell CJ, and Levy D Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score Circulation 110 2004 1920 1925
16. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, and Yoshii O Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2b and characterization of incomplete responders Am J Gastroenterol 10 1996 2144 2149
17. Quinones MA, Douglas PS, Foster E, Gorcsan J 3rd, Lewis JF, and Pearlman AS American College of Cardiology; American Heart Association; American College of Physicians; American Society of Internal Medicine Task Force on Clinical Competence. American College of Cardiology/American Heart Association clinical competence statement on echocardiography: a report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence Circulation 107 2003 1068 1089
18. (6 Suppl) Lown B, Calvert AF, Armington R, and Ryan M Monitoring for serious arrhythmias and high risk of sudden death Circulation 52 1975 III189 III198
19. Kondo Y, Yukinaka M, Nomura M, Nakaya Y, and Ito S Early diagnosis of interferon-induced myocardial disorder in patients with chronic hepatitis C: evaluation by myocardial imaging with 123I-BMIPP J Gastroenterol 35 2000 127 135
20. Fukuhara M, Matsumura K, Ohmori S, Yanai T, Tsubota Y, Abe I, and Fujishima M Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis Am J Hypertens 12 1999 519 523
21. Yamamoto T, Tsuchihashi T, Hayashi J, and Kashiwagi S Effect of interferon therapy on heart rate and sympathetic nervous system Fukuoka Igaku Zasshi 89 1998 207 215
22. Uehata A, Takase B, Nagai T, Hakamata N, Kastushika S, and Nishioka T Reversible endothelial dysfunction caused by interferon alpha therapy in chronic hepatitis C patients Circulation 96 Suppl-I 1997 I 728
23. Takase B, Uehata A, Fujioka T, Kondo T, Nishioka T, and Isojima K Endothelial dysfunction and decreased exercise tolerance in interferon-alpha therapy in chronic hepatitis C: relation between exercise hyperemia and endothelial function Clin Cardiol 24 2001 286 290
24. Higashi Y, and Yoshizumi M Exercise and endothelial function: role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients Pharmacol Ther 102 2004 87 96
25. Kemi OJ, Haram PM, Wisloff U, and Ellingsen O Aerobic fitness is associated with cardiomyocyte contractile capacity and endothelial function in exercise training and detraining Circulation 109 2004 2897 2904
26. Kadayifci A, Aytemir K, Arslan M, Aksoyek S, Sivri B, and Kabakci G Interferon-alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitis Liver 17 1997 99 102